Real-World Data Compares Semaglutide and SGLT2 Inhibitors Post-Heart Attack in Diabetics

Patients with type 2 diabetes are at significantly higher risk for acute coronary syndrome (ACS), such as heart attacks, and subsequent cardiovascular events. Two classes of medications, GLP-1 receptor agonists (like Semaglutide) and SGLT2 inhibitors, have demonstrated substantial cardiovascular benefits beyond glucose control. However, real-world comparative effectiveness data on these agents in diabetic patients immediately following an ACS event has been limited.

The analysis revealed that both Semaglutide and SGLT2 inhibitors were associated with significant reductions in cardiovascular events in this high-risk population. Patients treated with SGLT2 inhibitors showed a 28% reduction in the composite endpoint of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) compared to those on standard care, with p<0.001. The Semaglutide group demonstrated a 21% reduction in MACE compared to standard care, also with p<0.001. Importantly, SGLT2 inhibitors were associated with a 35% lower risk of heart failure hospitalization (p<0.001) and a 17% reduction in all-cause mortality (p=0.003) compared to the Semaglutide group in this real-world setting. Both drug classes significantly improved glycemic control, with an average HbA1c reduction of 1.2% for SGLT2 inhibitors and 1.5% for Semaglutide from baseline. Renal outcomes also favored SGLT2 inhibitors, showing a 43% reduction in the progression of kidney disease (p<0.001) compared to Semaglutide.